NASDAQ: CAI

Caris Life Sciences (CAI) Stock Analysis & Forecast

Nov 13 close

$23.04−0.92 (−3.8%)

Gekko Brief

AI summaryNov 9 close

Caris Life Sciences moved this week on third-quarter results, with revenue growth of 27% driven by molecular profiling services and approximately 61,500 clinical cases across over 358,000 total oncology tests. The company raised its 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%, while reporting lower quarterly profit tied to increased spending on its sales force, marketing and new tests. Earnings and revenues topped estimates, compared with $0.08 per share a year ago, and a separate filing disclosed FMR LLC and Abigail P. Johnson's 13.4% beneficial ownership stake as of 30 September 2026.

Shares closed at $25.57, up 1.3%, sitting between the 50-day average of $29.48 and the 200-day average of $21.67. The one-month return stands at -13.9% against a six-month return of 60.4%. The GekkoIndex reads 68.3, placing CAI in the Accumulation zone, up 15.4 over five days. The price sits 16.6% below Gekko Fair Value of $30.67.

The next earnings date falls on 25 February 2027, 107 days out and beyond a typical 20-trading-day hold. No insider, Congress or unusual options activity appears in the current windows. Two billionaire holders are recorded. Analyst coverage shows 6 buy and 3 hold ratings among 9 firms, with a consensus target of $32.46. Typical 20-day price movement runs near 12.5%, worth noting given recent volatility.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Caris Life Sciences price vs fair value

$31.33$23.04Nov ’25May ’26Nov ’26
Close $23.04200-day averageGekko Fair Value $31.33

Caris Life Sciences quick facts

Market cap
$6.61B
P/E ratio
14.4
Forward P/E
33.6
EPS, TTM
$1.66
Revenue, TTM
$1.05B
Profit margin
9.2%
Dividend yield
—
Beta
—
Volume
3.02M avg 3.95M
1-year return
−7.0%
Typical daily move
±10.8%
Typical 20-day move
±12.6%
50-day average
$29.39
200-day average
$21.63
Next earnings
Feb 25 after close
Shares outstanding
286.8M
52-week range
$14.19$36.50

Caris Life Sciences swing-trade checklist

Caris Life Sciences scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $23.04 sits between the 50-day ($29.39) and 200-day ($21.63) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    67.9, Accumulation

    Reading 67.9 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    26.5% below

    Price is 26.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

Caris Life Sciences stock chart and price history

Caris Life Sciences closed at $23.04 on Nov 13, 2026, −7.0% over the past year, inside a 52-week range of $14.19 to $36.50.

Close50-day average200-day averageVolume
Caris Life Sciences share price, past year, with 50-day and 200-day moving averages and volume$15$20$25$30$35DecJan 2026FebMarAprMayJunJulAugSepOctNov23.04

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−27.5%
3 months
+6.5%
6 months
+58.4%
1 year
−7.0%
The full CAI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CAI in Gekko

Follow Caris Life Sciences through every session

Put CAI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CAI in GekkoFree for 7 days. No credit card required.

About Caris Life Sciences

Caris Life Sciences applies artificial intelligence to molecular profiling, giving clients in the United States and abroad detailed analysis of disease at the molecular level. It is known for tools that examine tissue and blood samples to inform cancer-related medical decisions, combining large sets of molecular data with machine learning to guide treatment choices.

Its offerings include MI Profile, which studies tissue samples, and Caris Assure, a blood-based test used in cancer care. Beyond these diagnostic products, the company works with biopharmaceutical firms, supporting their research and development through laboratory services, data analysis, and collaborative research projects.

Caris Life Sciences was founded in 2008 and is headquartered in Irving, Texas. Its shares are listed on the NASDAQ under the ticker CAI.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
carislifesciences.com

Caris Life Sciences GekkoIndex: the smart money zone

Caris Life Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.9, in the Accumulation zone, up 0.1 points over five sessions.

010067.9Accumulation

Up 0.1 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying33+1.3%+2.3%+5.0%+0.4%
Accumulation (current zone)122−0.4%+0.6%+2.4%+2.4%
Neutral170+1.2%+1.7%+1.6%+3.8%
Distribution18+0.5%−0.4%+7.9%+23.5%
Selling2Too few readings yet

Average CAI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the CAI price, zone by zone.Track CAI in Gekko

Is Caris Life Sciences stock overvalued? Gekko Fair Value

Caris Life Sciences trades 26.5% below Gekko Fair Value of $31.33, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Caris Life Sciences shares are worth, recalculated every trading day.

$31.33

Gekko Fair Value, Nov 14, 2026

26.5% Undervalued

At the end of Sep 2026 the price was 25.7% above the estimate.

Gekko Fair ValueShare price, month end
$31$23Sep 2026OctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CAI in Gekko

Caris Life Sciences insider and Congress trading

No open-market insider purchases were filed for Caris Life Sciences, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CAI in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CAI insider filing, plotted on the chart in Gekko.Open CAI in Gekko

Congress trades last 90 days

No trades in CAI were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CAI, plotted on the chart in Gekko.Open CAI in Gekko

Buybacks

Caris Life Sciences has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$10.01M
As a share of market cap
0.15%

From company filings.

Hedge funds and billionaires quarter ended Mar 31

2of the funds Gekko tracks hold CAI.

0added1opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Caris Life Sciences earnings: next date and track record

Caris Life Sciences reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±17.5%average move across the report
3 of 6reports followed by a gain

Share-price move across each report

+13.5%Aug ’25−21.1%Nov ’25+10.0%Feb ’26−15.6%May ’26+24.2%Aug ’26−20.8%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
CAI reported record Q3 2026 results with volume up 21% to 61,500 cases and revenue growing 27% to $275 million. The company launched 4 products in 2026 including Caris Assure for therapy selection and is entering the MRD/monitoring market with Caris Assure Therapy Response Monitoring. Early cancer detection product Caris Detect is gaining traction with national marketing campaigns. Growth was achieved while maintaining profitability and self-funding all investments.
Guidance
Management expects Q3's accelerating volume growth trend to continue into Q4 2026. Caris Confirm, a whole-genome MRD assay, is targeted for December launch as the fifth product of the year. Additional market expansion for Caris Detect planned for Q4 and beyond.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$0.05
est $0.03
+77.7%$275.4M
est $255.4M
+7.8%−20.8%
Aug 5, 2026$0.00
est $0.01
−139.2%$263.7M
est $238.1M
+10.8%+24.2%
May 7, 2026$0.00
est −$0.02
+91.0%$216.2M
est $209.4M
+3.2%−15.6%
Feb 26, 2026$0.28
est $0.10
+180.0%$292.9M
est $240.4M
+21.8%+10.0%
Nov 5, 2025$0.08
est −$0.08
+200.0%$216.8M
est $280.9M
−22.8%−21.1%
Aug 12, 2025−$0.54
est −$0.21
−157.1%$181.4M
est $137.7M
+31.8%+13.5%
Jun 9, 2025−$0.35
est −$0.22
−60.3%$120.9M
est $138.0M
−12.4%—
Nov 5, 2021$2.95
est $0.61
+383.6%$100.8M
est $90.24M
+11.7%—

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Caris Life Sciences stock forecast and analyst price targets

Analysts’ average 12-month price target for Caris Life Sciences is $34.23, +48.6% from the last close, from 11 firms rating the stock in the last 90 days.

$34.23consensus 12-month target, +48.6% from the last close
Low $25High $38
Buy8
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Piper SandlerHold, reiterated$25+8.5%
Nov 10GuggenheimBuy, reiterated$36+56.3%
Nov 6CitiBuy, maintained$36+56.3%
Nov 5Goldman SachsBuy, maintained$35+51.9%
Nov 5Robert W. BairdBuy, maintained$33+43.2%
+2.4%average 20-day move after past Accumulation readings
±10.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Caris Life Sciences market cap and key statistics

Caris Life Sciences’s market cap is $6.61B, with a P/E ratio of 14.4 and revenue of $1.05B over the last twelve months.

Valuation

Market cap
$6.61B
P/E ratio
14.4
Forward P/E
33.6
EPS, TTM
$1.66
Gekko Fair Value
$31.33

Trading

Volume
3.02M
Avg volume, 20 days
3.95M
52-week high
$36.50
52-week low
$14.19
Shares outstanding
286.8M

Financials

Revenue, TTM
$1.05B
Profit margin
9.2%
Return on equity
17.2%
Quarterly earnings growth, YoY
−37.5%

Risk and income

Typical daily move
±10.8%
Typical 20-day move
±12.6%

Caris Life Sciences stock news this week

2 headlines about Caris Life Sciences from the past week, newest first, each linking to the publisher.

Caris Life Sciences peers

Caris Life Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Caris Life Sciences stock FAQ

What is Caris Life Sciences’s market cap?

Caris Life Sciences’s market cap is $6.61B at the Nov 13, 2026 close of $23.04, with 286.8M shares outstanding. The shares trade on a P/E ratio of 14.4.

What is the Caris Life Sciences stock forecast?

The consensus analyst 12-month price target for Caris Life Sciences is $34.23, +48.6% from the last close. Of the 11 firms that rated the stock in the last 90 days, 8 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Caris Life Sciences stock overvalued or undervalued?

On Gekko’s estimate Caris Life Sciences is undervalued: the Nov 13, 2026 close of $23.04 is 26.5% below Gekko Fair Value of $31.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Caris Life Sciences report earnings next?

Caris Life Sciences is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of $0.06 per share on revenue of $290.2M. Caris Life Sciences beat the earnings estimate in 5 of its last 8 reports, moving 17.5% on average across the report.

What is Caris Life Sciences’s 52-week high and low?

Caris Life Sciences’s 52-week high is $36.50 and its 52-week low is $14.19; it closed at $23.04 on Nov 13, 2026, −7.0% over the past year. Over the last five years the shares peaked at $42.50 on Aug 22, 2025.

Is Caris Life Sciences stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Caris Life Sciences the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.